Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Sorafenib Resistance in Advanced HCC
NCT02733809Phase 4Unknown
- Sponsor
- King Saud University
- Start
- Jan 2014
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sorafenib in hepatocellular carcinoma (HCC), sponsored by King Saud University. Primary endpoint: Overall and disease-free survival genes at 10 years. Status: unknown.
02
Drugs
sorafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02733809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02733809.